Antoine Kimmoun
Prof Antoine Kimmoun is an expert in Critical care at Centre Hospitalier Universitaire de Nancy (France). As of October 2026, ScienceLeadR ranks Antoine Kimmoun in the top 1% of experts worldwide for COVID-19, Coronavirus Infections and Intensive Care Units. Antoine Kimmoun has authored 284 publications, the most recent in 2026, and is an investigator in 39 clinical trials, 9 of them ongoing. SLR score: 1,357 (community average: 125). How the SLR is computed.
LeadR Profile
Critical care
Subspecialties: Cardiology - Public Health - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 284
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Effect of interferon gamma as a treatment for post-aggressive immunosuppression in critically ill (INFINITY trial): study protocol for a randomised Bayesian double-blind controlled trial. PMID 42933837 — interferon-gamma, critical illness, therapeutics, immunosuppression therapy | BMJ Open | 2026 | 0 |
| Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury. PMID 42873070 — continuous renal replacement therapy, mortality, kidney, respect, critical illness, therapeutics, renal replacement therapy, acute kidney injury | N Engl J Med Top journal | 2026 | 1 |
| Cardiogenic shock supported with VA-ECMO: Association between cDPP3 concentrations and outcomes in a post hoc analysis of the ADRECMO cohort. PMID 42575460 — shock, cardiogenic, heart failure, extracorporeal membrane oxygenation, biomarkers, peptide hydrolases | J Card Fail | 2026 | 0 |
| Transfusion intensity in the ICU: Reasons and triggers. PMID 42541477 — blood transfusion, hematology, hemorrhage, critical care, critical illness, intensive care units | Transfusion | 2026 | 0 |
| Complement augments antibody neutralization of SARS-CoV-2 variants. PMID 42485435 — sars-cov-2, virion, antibodies, viruses, immunity, complement system proteins, severe acute respiratory syndrome-related coronavirus | Sci Transl Med | 2026 | 0 |
Clinical Studies 39
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 29
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Early Corticosteroids in Severe Influenza Pneumonia NCT07786662 — injections, hygiene, dexamethasone, adrenal cortex hormones, pneumonia, influenza, human, therapeutics, intensive care units, respiratory distress syndrome, random allocation, communicable diseases, injections, intravenous | Phase 3 | Not yet recruiting | 2026 |
| Study Evaluating Multifaceted Support for the Implementation of Recommendations for the Prevention and Management of Anemia in Intensive Care Units NCT07771192 — anemia, hospital mortality, intensive care units | N/A | Not yet recruiting | 2026 |
| Inhaled isoflurane for SEdation of invasively ventilated PaTIents with cardiogenic shock on extracOrporeal membrane oxygeNation (INSEPTION) 2023-510261-94-00 — shock, cardiogenic, extracorporeal membrane oxygenation, isoflurane, membranes | Phase 3 | Recruiting | 2026 |
| Dapagliflozin for Cardio renal Protection After ICU Discharge NCT07025629 — kidney diseases, sodium-glucose transporter 2 inhibitors, heart failure, heart, recycling, tablets, kidney, biomarkers, critical illness, intensive care units, random allocation, cardio-renal syndrome | Phase 3 | Recruiting | 2025 |
| A Phase 1b 2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ AK1967) in Critical Cardiovascular Care NCT06832722 — safety, shock, cardiogenic, multiple chronic conditions, peptide hydrolases, antibodies, monoclonal, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map